Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Beam Therapeutics Inc.

    NASDAQ: BEAM · Real-Time Price · USD
    17.14
    0.43 (2.57%)
    At close: Jun 24, 2025, 3:59 PM
    17.15
    0.03%
    After-hours: Jun 24, 2025, 07:49 PM EDT
    2.57%
    Bid 17.13
    Market Cap 1.72B
    Revenue (ttm) 63.58M
    Net Income (ttm) -387.34M
    EPS (ttm) -4.61
    PE Ratio (ttm) -3.72
    Forward PE -3.61
    Analyst Buy
    Ask 17.4
    Volume 1,009,524
    Avg. Volume (20D) 2,256,067
    Open 17.15
    Previous Close 16.71
    Day's Range 16.86 - 17.38
    52-Week Range 13.53 - 35.25
    Beta 2.08

    About BEAM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BEAM
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BEAM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Beam Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -19.32%
    Beam Therapeutics shares are trading lower followi... Unlock content with Pro Subscription
    3 months ago
    -9.8%
    Beam Therapeutics shares are trading lower after the company announced a $500 million offering.
    news image

    15 hours ago · schaeffersresearch.com

    Top Stock Pick Report: V-Shaped Rallies Everywhere

    Subscribers to  Chart of the Week  received this commentary on Sunday, June 22.

    news image

    4 days ago · seekingalpha.com

    Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

    Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from p...

    news image

    2 weeks ago · zacks.com

    Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

    Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

    news image

    2 weeks ago · zacks.com

    BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

    Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

    news image

    1 month ago · zacks.com

    BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

    Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.

    news image

    1 month ago · fool.com

    Why Beam Therapeutics Stock Tanked on Tuesday

    Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced...

    news image

    1 month ago · zacks.com

    Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

    Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago.

    news image

    2 months ago · schaeffersresearch.com

    Power Ranking Our Top Stock Picks of 2025

    Subscribers to  Chart of the Week  received this commentary on Sunday, March 30.

    news image

    2 months ago · invezz.com

    Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

    Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

    news image

    2 months ago · zacks.com

    BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

    The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

    Add to Watchlist